ObjectiveBreast cancer (BC) is a common malignancy among women worldwide. Fibroblast
growth factor receptor 2 (FGFR2) rs2981582 is reported to play a vital role
in BC development. However, the relationship between them remains
unclear.MethodsNinety-five patients and 140 healthy controls were enrolled in the study.
Plasma DNA was genotyped by the MassARRAY method. A meta-analysis was
conducted to clarify the effect of FGFR2 polymorphism on BC risk.ResultsOur case-control study results revealed a significant difference in CC, TC,
and TT genotypes between patients and controls. Logistic regression analysis
showed that TT and TC genotype and the dominant mode were significantly
correlated with BC development [odds ratio (OR) = 1.21, 95% confidence
interval (CI): 1.050–2.27; OR = 1.81, 95% CI: 1.24–2.73; OR = 2.15, 95% CI:
1.25–5.31, respectively], even after adjusting for age, body weight,
drinking, smoking, and estrogen receptor status. A meta-analysis of 15
studies showed significant differences among the dominant, recessive,
heterozygote, and homozygote models between patients and controls.ConclusionsOur results showed an association of FGFR2 rs2981582 polymorphism with BC in
an Asian population. However, a more comprehensive study of the relationship
between the polymorphism and BC is still needed.